5e5 of anti-FAP CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human FAP, His Tag (Cat. No. FAP-HP245) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
Anti-FAP Antibody, Mouse IgG2a (FAP5) captured on CM5 chip via anti-mouse antibodies surface can bind Rat FAP, His Tag (Cat. No. FAP-R5246) with an affinity constant of 0.839 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
OMTX-705 | OMTX-705 | Phase 1 Clinical | Oncomatryx Biopharma Sl | Solid tumours | Details |
FAP-DR5 | RG-7386; RO-6874813 | Millennium Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd | Details | ||
177Lu-FAP-2286 | 177Lu-FAP-2286 | 3b Pharmaceuticals | Solid tumours | Details | |
68Ga-FAP-2286 | 68Ga-FAP-2286; 68-Ga-FAP-2286 | Phase 2 Clinical | 3b Pharmaceuticals | Solid tumours; Neoplasm Metastasis | Details |
MP-0310 | MP-0310; AMG-506 | Phase 1 Clinical | Molecular Partners Ag, Amgen Inc | Solid tumours | Details |
Simlukafusp alfa | FAP-IL2v; RG-7461; aFAP-IL2v; RO-6874281; FAP-IL2v FP | F. Hoffmann-La Roche Ltd | Details | ||
Talabostat (BioXcel) | PT-100; BXCL-701 | Phase 2 Clinical | Inveni | Prostatic Neoplasms | Details |
Talabostat | PT-100 | Midatech Pharma Plc | Details | ||
RO-7300490 | RO-7300490; RG-6189 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours; Neoplasms | Details |
Nectin4/FAP-targeted CAR-T cell therapy (The Sixth Affiliated Hospital of Wenzhou Medical University) | Phase 1 Clinical | Wenzhou Medical University | Solid tumours | Details |
This web search service is supported by Google Inc.